Print

Rockland Immunochemicals Awarded Phase I SBIR Funding to Develop Generic Antibodies "Biosimilars" for the Treatment of Cancer  
10/26/2010 9:02:10 AM

GILBERTSVILLE, Pa.--(BUSINESS WIRE)--Rockland Immunochemicals Inc., (www.rockland-inc.com) a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop Generic Antibodies “Biosimilars” for the Treatment of Cancer.
//-->